MediciNova announces new data, results of Phase 2 trial of MN-166 in GBM

MediciNova announced that the company’s collaborator has presented new data and results of a Phase 2 clinical trial of MN-166 in glioblastoma patients at the 28th Annual Meeting of the Society for Neuro-Oncology held November 15 – 19, 2023 in Vancouver, Canada. The presentation also included data from preclinical studies which evaluated the combination of MN-166 and anti-PD1 or anti-PD-L1 therapy in GBM models. The primary endpoints of this Phase 2 clinical trial were safety and tolerability of MN-166 and temozolomide combination treatment and efficacy of the combination treatment defined as progression-free survival rate at 6 months using the RANO criteria. MN-166 and TMZ combination treatment was safe and well-tolerated, and no unexpected adverse effects were reported. The trial enrolled a total of 62 patients, including 36 newly diagnosed GBM patients and 26 recurrent GBM patients. Progression-Free Survival at 6 months was 44% for new GBM and 31% for recurrent GBM. Immunohistochemistry evaluation was performed for the patients whose pre-treatment tumor tissue samples were available from resected tumors at the initial surgery or biopsy to evaluate MIF, pERK, Ki67, CD3, CD11b, and CD74. CD3 expression was a good predictor for tumor progression at five months in recurrent glioblastoma subjects treated with MN-166 and TMZ as subjects with progression had higher CD3 tumor infiltration than subjects with no progression.